Ledgertech SE becomes SynBiotic SE

For centuries, researchers and users have known about the power of herbal substances – especially “Cannabis sativa” – for use in medicine, cosmetics and nutrition.

Scientific research is increasingly demonstrating what our ancestors knew instinctively and through centuries-old traditions: the active ingredients of the cannabis sativa plant, the so-called cannabinoids, show many positive effects when used for medical purposes, such as chronic pain and epilepsy. But ingredients of the cannabis sativa plant are also being used more and more in the field of cosmetics and food supplements.

Synbiotic SE pursues the goal of mapping the entire value chain of the cannabis sativa plant for the benefit of people: from basic research to the synthetic production of these substances to the development and approval of innovative medicines as well as over-the-counter wellness products based on cannabinoids.

In addition, we will gradually turn to other herbal ingredients and expand our portfolio step by step.

To reflect the new strategy in its name, the Annual General Meeting of Ledgertech SE on April 8 decided unanimously to change its name to Synbiotic SE. As soon as the name change is registered, the shares in the various databases such as comdirect, Onvista and Bloomberg are also converted. Until then, our shares still trade under “Ledgertech” (ISIN: DE000A2LQ777)

The market

A rethink is taking place all over the world: Based on solid scientific discoveries and profound medical research, the way in which society, politics, the pharmaceutical industry and above all also the individual consumer cannabis and other medicinal plants such as, for example, has changed within a few years Look at magic mushrooms and DMT, fundamentally changed. In the United States, the cannabis market has been almost completely legalized and opened up for medical purposes as well as for pure enjoyment – the so-called “recreational use”. Large, multi-billion dollar companies such as Tilray, Canopy Growth and GW Pharmaceuticals emerged within a few years. The European Union is in the process of following this path: With more than 700 million inhabitants in continental Europe and 500 million in the EU, the sales potential in the cannabis market is estimated to be around USD 136 billion by 2028 (Prohibition Partners study). A few billion companies will also grow here, and we want to be one of them.

Our strategy

With a focused buy-and-build strategy, we want to build a diversified group of companies that includes the alternative production of functionally superior cannabinoids and other psychoactive molecules as well as the development of wellness products for end customers under our own brands.

In the growth market of nature-based medical and wellness products, we want to focus on the following four areas:

Synthetic production
While today’s medical marijuana mainly includes flowers and plant extracts, the ratio of active ingredients to the resources required for production on a larger scale has proven unsustainable. Different harvests and varying active substance contents make it difficult to use them as pharmaceutical therapeutic agents. However, synthetic biology will soon be able to produce natural and superior cannabinoids.

Drug development
In order to be fully effective, many active substances – especially THC, the psychoactive ingredient of cannabis – require a concentration that the responsible pharmaceutical authorities classify as medicinal products and therefore as licensed and prescription-only. The approval of such a drug is lengthy, but it also provides comprehensive patent and brand protection and, if successful, often guarantees a monopoly position in a billion dollar market.

Food supplements
Extracts from hemp without THC are sold worldwide as dietary supplements. The goal is to support the well-being of consumers. Above all, the purity and transparency regarding the products (cannabinoid profile, free of pesticides, heavy metals and bacteria) and a strong brand count.

Cosmetic products
Not only in the body, but also on the skin, cannabinoids can interact with the body’s endocannabinoid system. Cannabidiol (CBD) is now listed as a permitted cosmetic ingredient in the EU-CosIng database. As with food supplements, in addition to the highest quality of the products, trust in a strong brand is particularly important.

We are in discussion with various potential acquisition candidates in all four areas and are confident that we will be able to report first acquisitions in a timely manner.